Trump Eyes Psychedelic Executive Order, Signals Policy Shift
Administration reportedly preparing executive order on ibogaine research, marking potential expansion beyond cannabis into broader psychedelic therapeutics market.
The Trump administration prepares to issue an executive order directing federal agencies to explore therapeutic applications of ibogaine, a psychedelic compound derived from African shrubs. The directive, expected within days according to government sources, represents the administration's first concrete policy signal on psychedelic medicine beyond traditional cannabis frameworks.
The executive order stops short of rescheduling ibogaine from its current Schedule I classification but establishes federal research pathways for studying the compound's potential in treating addiction and PTSD. This approach mirrors recent FDA breakthrough therapy designations for psilocybin and MDMA, creating regulatory momentum that benefits publicly traded psychedelic companies like Compass Pathways and MindMed.
Cannabis industry stakeholders view the ibogaine initiative as validation of broader alternative medicine acceptance at the federal level. The policy shift occurs as traditional cannabis companies face margin compression and seek diversification into adjacent therapeutic markets. Several major operators already invest in psychedelic research divisions, positioning for potential regulatory changes that could unlock new revenue streams.
The timing aligns with growing institutional interest in psychedelic therapeutics, where venture capital funding reached $185 million in 2024 despite overall biotech sector challenges. Unlike cannabis, psychedelics face less state-federal regulatory conflict, potentially offering cleaner commercialization pathways for companies navigating complex compliance landscapes.
Market analysts expect the executive order to accelerate private investment in psychedelic research while providing political cover for broader controlled substance policy reforms. The administration's willingness to engage with Schedule I substances through executive action suggests potential future flexibility on cannabis rescheduling, though no direct policy connections exist between the initiatives.